BeiGene
Yahoo Finance • last month
Here’s Why BeiGene, Ltd. (BGNE) Rallied in Q3
Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua International and Global Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded he... Full story
Yahoo Finance • 4 months ago
Beyond the Balance Sheet: What SWOT Reveals About BeiGene Ltd (BGNE)
BeiGene Ltd's robust product pipeline and global expansion underscore its market potential. Financial analysis reveals significant growth in product revenue, yet operational challenges persist. Opportunities in international markets and in... Full story
Yahoo Finance • 7 months ago
10 Most Promising Stocks to Buy Before They Take Off
In this article, we discuss the 10 most promising stocks to buy before they take off. To skip the detailed analysis of the current earnings week, go directly to the 5 Most Promising Stocks to Buy Before They Take Off. Meta Grows Revenue b... Full story
Yahoo Finance • 8 months ago
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the eve... Full story
Yahoo Finance • 9 months ago
Genmab: Growth Is Still a Better Choice
Genmab AS (NASDAQ:GMAB) is one of the largest Danish pharmaceutical companies focused on developing medicines to treat patients with cancer, multiple sclerosis, thyroid eye disease and various autoimmune diseases. Investment thesis Genma... Full story
Yahoo Finance • 10 months ago
10 Blue-Chip Stocks At 52 Week Lows
In this piece, we will take a look at the ten blue chip stocks at 52 week lows. If you want to skip the latest stock market news, then you can take a look at the 5 Blue-Chip Stocks At 52-Week Lows. The end of January has provided the medi... Full story
Yahoo Finance • 11 months ago
A Look At The Intrinsic Value Of BeiGene, Ltd. (NASDAQ:BGNE)
Key Insights The projected fair value for BeiGene is US$209 based on 2 Stage Free Cash Flow to Equity With US$180 share price, BeiGene appears to be trading close to its estimated fair value Analyst price target for BGNE is US$285, which... Full story
Yahoo Finance • 11 months ago
12 High Growth International Stocks to Buy
In this article, we discuss the 12 high growth international stocks to buy. If you want to read about some more high growth international stocks, go directly to 5 High Growth International Stocks to Buy. There is general optimism on Wall... Full story
Yahoo Finance • 11 months ago
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
U.S. label update includes superior progression-free survival results from the Phase 3 ALPINE head-to-head trial of BRUKINSA versus IMBRUVICA® (ibrutinib) in Relapsed or Refractory CLL ALPINE is the only Phase 3 Bruton’s tyrosine kinase (... Full story
Yahoo Finance • last year
BAKER BROS. ADVISORS LP Bolsters Position in BeiGene Ltd
Significant Addition to BeiGene Holdings BAKER BROS. ADVISORS LP (Trades, Portfolio), a prominent investment firm, has recently expanded its investment in BeiGene Ltd (NASDAQ:BGNE) with a substantial acquisition of shares. On November 14,... Full story
Yahoo Finance • last year
Health Care Roundup: Market Talk
The biotech company’s 3Q results beat was fueled in part by higher revenue overseas and the success of blood-cancer drug Brukinsa, analysts Jason Siu and Matthew Law say in a note. CCB lifts BeiGene’s H-shares target 0.5% to HK$150.80, to... Full story
Yahoo Finance • last year
BeiGene, Ltd.'s (NASDAQ:BGNE) one-year returns climbed after last week's 8.9% gain, institutional investors must be happy
Key Insights Significantly high institutional ownership implies BeiGene's stock price is sensitive to their trading actions A total of 5 investors have a majority stake in the company with 52% ownership Using data from analyst forecasts a... Full story
Yahoo Finance • last year
Bragar Eagel & Squire, P.C. Is Investigating BeiGene and Fox and Encourages Investors to Contact the Firm
NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims BeiGene, Ltd. (NASDAQ: BGNE) and Fox Corp. (NASDAQ: FOX, FOXA). Our investiga... Full story
Yahoo Finance • last year
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support Investigational New Drug filing BASEL, Switzerland & BEIJING & CAMBRIDGE,... Full story
Yahoo Finance • last year
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass, July 07, 2023--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will host an investor Research and Developme... Full story
Yahoo Finance • last year
Bragar Eagel & Squire, P.C. Is Investigating Fox and BeiGene and Encourages Investors to Contact the Firm
NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corp. (NASDAQ: FOX, FOXA) and BeiGene Limited (NASDAQ: BGNE). Our... Full story
Yahoo Finance • last year
ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
NEW YORK, July 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from alleg... Full story
Yahoo Finance • last year
Bragar Eagel & Squire, P.C. Is Investigating EPAM, Castle, BeiGene and Fox and Encourages Investors to Contact the Firm
NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against EPAM Systems, Inc. (NYSE: EPAM), Castle Biosciences, Inc. (NASDAQ: CS... Full story
Yahoo Finance • last year
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
WHY: NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allega... Full story
Yahoo Finance • last year
業界領先的投資者權益律所 ROSEN 鼓勵 BeiGene, Ltd. 投資者查詢 BGNE 證券集體訴訟調查狀況
紐約, June 26, 2023 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 宣布代表 BeiGene, Ltd. (NASDAQ: BGNE) 的股東調查潛在的證券索賠，原因是有指控稱 BeiGene 可能向投資大眾發布了嚴重誤導性的商務資訊。 影響：倘若您曾購買 BeiGene 證券，您可能有權透過勝訴收費安排獲得賠償，而無需支付任何自付費用或訟費。Rosen Law Firm 正在準備發起一項集體訴訟以... Full story
